Publications by authors named "R Tartarini"
Background: Novel biomarkers, such as plasma microRNAs (miRs), are needed to help guide clinical decision-making for the type of chemotherapy to use in patients with advanced pancreatic ductal adenocarcinoma (PDAC). This study assessed the ability of plasma miRs to predict optimal treatment response from FOLFIRINOX or gemcitabine--paclitaxel in these patients.
Methods: Next-generation sequencing (NGS) was performed for biomarker discovery in pre-treatment plasma samples from advanced PDAC patients subsequently treated with FOLFIRINOX (n = 12) or gemcitabine--paclitaxel (n = 12).
Observed versus expected morbidity and mortality in patients undergoing mitral valve repair.
Interact Cardiovasc Thorac Surg
October 2022
Objectives: Mitral valve repair (MVP) is the gold standard treatment for degenerative mitral regurgitation. With the expansion of transcatheter technologies, this study compares the outcome of MVP in low-risk and non-low-risk patients to serve as a benchmark.
Methods: This retrospective, single-institution study examined all patients who underwent MVP for primary mitral regurgitation from 2005 to 2018.
Objectives: As the application of transcatheter aortic valve replacement (TAVR) expands, the longitudinal implications of periprocedural complications are increasingly relevant. We examine the influence of TAVR complications on midterm survival.
Methods: Patients undergoing transfemoral TAVR at our institution between November 2011 and June 2018 were reviewed.
Background: Guidelines outlining the role of surgical embolectomy for acute pulmonary embolism remain consensus based; however, recent outcomes have improved compared with traditional experiences. This study examined contemporary outcomes of patients treated for acute pulmonary embolism on a nationwide scale.
Methods: Patients undergoing systemic thrombolysis, catheter-directed therapy, and surgical embolectomy for acute pulmonary embolism from 2010 to 2014 in the National Inpatient Sample were included.
Article Synopsis
- Fibrous dysplasia (FD) is a rare bone disease where the normal bone is replaced by a different kind of tissue, and it can come in three forms.
- A case study talked about a 52-year-old man who had a mass on his skull that grew a lot over 18 years while he just monitored it.
- The story shows that keeping an eye on FD is really important, and sometimes it's better to act sooner instead of waiting for something to get worse.